Tiziana Life Sciences is trading at $1.10, up 15.34%, with no clear after-hours catalyst identified.
- No new company announcement dated September 29 was found that clearly explains the move.
- The latest major company news was September 28, when the first three participants received doses in the Phase 2a BANYAN ALS trial; that timing alone does not establish it caused the move.
- The supplied market context shows mixed major indexes, not a broad same-direction rally.